EMA Authorised: Rilutek (riluzole) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA authorised Rilutek (riluzole) for use in amyotrophic lateral sclerosis, with Sanofi Winthrop Industrie as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Rilutek (riluzole)

Snippet

Status: Authorised. Therapeutic area: Amyotrophic Lateral Sclerosis. MAH: Sanofi Winthrop Industrie. Decision date: 24/07/2024